Acute graft-versus-host disease (aGVHD) is partly mediated through activated T cells, and these cells are known to express the high-affinity receptor for interleukin 2 (IL-2R). Denileukin diftitox is composed of human IL-2 and diphtheria toxin that is cytotoxic to activated lymphocytes expressing the high-affinity IL-2R. We describe the results of a phase II study of denileukin diftitox in 22 patients with steroid-resistant aGVHD. Twenty patients were treated at dose level 1 (4.5 microg/kg daily on days 1-5 and then weekly on study days 8, 15, 22, and 29), and 2 patients were treated at dose level 2 (9.0 microg/kg delivered on the same schedule). Dose level 2 was associated with grade 3/4 renal and hepatic toxicity and vascular leak syndrome, and no further patients were treated at this level. Dose level 1 was generally well tolerated. The response of aGVHD was assessed at study days 36 and 100. Nine patients (41%) responded, all with a complete response at study day 36, and 6 patients (27%) responded at study day 100 (4 complete responses and 2 partial responses). Denileukin diftitox has promising activity in steroid-resistant aGVHD, and further study is warranted.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.bbmt.2004.11.022 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Efficacy and Safety of Denileukin Diftitox-Cxdl, an Improved Purity Formulation of Denileukin Diftitox, in Patients With Relapsed or Refractory Cutaneous T-Cell Lymphoma.
J Clin Oncol
December 2024
Department of Dermatology, The University of Texas-MD Anderson Cancer Center, Houston, TX.
Purpose: Denileukin diftitox (DD)-cxdl is a fusion protein comprising diphtheria toxin fragments A and B and human interleukin-2. This phase III, multicenter, open-label, single-arm registrational trial evaluated the efficacy and safety of DD-cxdl in patients with relapsed/refractory (R/R) cutaneous T-cell lymphoma (CTCL).
Patients And Methods: In the main study, which followed a dose-finding lead-in, DD-cxdl was administered intravenously daily (5 days; 9 µg/kg/d once daily) every 21 days for up to eight cycles.
Compromising the immunogenicity of diphtheria toxin-based immunotoxins through epitope engineering: An in silico approach.
J Pharmacol Toxicol Methods
December 2024
Faculty of Pharmacy, Baqiyatallah University of Medical Sciences, Tehran, Iran. Electronic address:
Immunotoxins are genetically engineered recombinant proteins consisting of a targeting moiety, such as an antibody, and a cytotoxic toxin moiety of microbial origin. Pseudomonas exotoxin A and diphtheria toxin (DT) have been abundantly used in immunotoxins, with the latter applied as the toxin moiety of the FDA-approved drug Denileukin diftitox (ONTAK®). However, the use of immunotoxins provokes an adverse immune response in the host body against the toxin moiety, limiting their efficacy.
View Article and Find Full Text PDFIntraperitoneal immunotherapy with denileukin diftitox (ONTAK) in recurrent refractory ovarian cancer.
Gynecol Oncol
December 2024
UW Medicine Cancer Vaccine Institute, University of Washington, 850 Republican St, Seattle, WA 98195, United States of America.
Article Synopsis
- Denileukin diftitox (ONTAK) is a fusion protein that can deplete regulatory T cells, which are linked to poor outcomes in ovarian cancer, and this study aimed to assess its safety and effects when given directly into the abdomen of patients with advanced ovarian cancer.
- A phase I trial included 10 patients who received ONTAK at escalating doses, revealing a maximum tolerated dose of 15 μg/kg with mostly mild side effects, though one patient experienced a severe reaction at the highest dose.
- While some patients showed a decrease in CA-125 levels (a marker for ovarian cancer), there were no significant changes in the overall cancer response, although ONTAK successfully reduced regulatory T cells in both blood and
Novel Pharmacological Treatment Options of Steroid-Refractory Graft-versus-Host Disease.
Adv Hematol
December 2023
The Christ Hospital Network, Cincinnati, Ohio, USA.
Article Synopsis
- Graft-versus-host disease (GVHD) is a serious complication of hematopoietic stem cell transplants, with current steroid treatments being ineffective in 30-50% of cases, leading to high mortality rates in steroid-refractory GVHD (SR-GVHD).
- This review analyzes new therapeutic options for SR-GVHD, emphasizing experimental drugs like ruxolitinib, monoclonal antibodies, and other agents that show promise but require more research on their safety and effectiveness.
- While some agents demonstrate potential for improving treatment outcomes in chronic GVHD, further rigorous trials are needed to confirm their efficacy on a larger scale.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!